Trial Profile
Panretinal Photocoagulation Versus Panretinal Photocoagulation Plus Intravitreous Ranibizumab for High Risk Proliferative Diabetic Retinopathy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2011
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic retinopathy
- Focus Therapeutic Use
- Acronyms IRaHi
- 01 Nov 2011 Results published in the Acta Ophthalmologica.
- 03 Aug 2011 Actual end date (February 2011) added as reported by ClinicalTrials.gov.
- 03 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.